The potential for targeting the STAT3 pathway as a novel therapy for melanoma

Future Oncology

Volumn 9, Issue 7, 2013, Pages 925-927

  Lesinski, Gregory B ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

cytokine; immunotherapy; Jak STAT; Jak2; melanoma; STAT3

Indexed keywords

JANUS KINASE 2 INHIBITOR; STAT3 PROTEIN;

CANCER IMMUNOTHERAPY; CANCER THERAPY; DRUG POTENCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; MICE; MOLECULAR TARGETED THERAPY; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES;

EID: 84880233868     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.83     Document Type: Review

References (20)

1. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
2. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J. Clin. 62(5), 309-335 (2012).
3. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 24(2), 315-327 (2005).
4. Niu G, Bowman T, Huang M et al. Roles of activated Src and STAT3 signaling in melanoma tumor cell growth. Oncogene 21(46), 7001-7010 (2002).
5. Xie TX, Huang FJ, Aldape KD et al. Activation of STAT3 in human melanoma promotes brain metastasis. Cancer Res. 66(6), 3188-3196 (2006).
6. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 19(21), 2607-2611 (2000).
7. Takeda K, Noguchi K, Shi W et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA 94(8), 3801-3804 (1997).
8. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 9(11), 798-809 (2009).
9. Zhang X, Yue P, Page BD et al. Orally bioavailable small-molecule inhibitor of transcription factor STAT3 regresses human breast and lung cancer xenografts. Proc. Natl Acad. Sci. USA 109(24), 9623-9628 (2012).
10. Yue P, Turkson J. Targeting STAT3 in cancer: How successful are we? Expert Opin. Investig. Drugs 18(1), 45-56 (2009).
11. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of STAT3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 69(6), 2506-2513 (2009).
12. Kong LY, Gelbard A, Wei J et al. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin. Cancer Res. 16(9), 2550-2561 (2010).
13. Kortylewski M, Swiderski P, Herrmann A et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27(10), 925-932 (2009).
14. Kujawski M, Zhang C, Herrmann A et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res. 70(23), 9599-9610 (2010).
15. Bill MA, Fuchs JR, Li C et al. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol. Cancer 9, 165 (2010).
16. Bill MA, Nicholas C, Mace TA et al. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS ONE 7(8), e40724 (2012).
17. Liu F, Cao J, Wu J et al. STAT3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J. Invest.Dermatol. doi:10.1038/jid. 2013.32 (2013) (Epub ahead of print).
18. Becker TM, Boyd SC, Mijatov B et al. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene doi:10.1038/onc.2013.45 (2013) (Epub ahead of print).
19. Girotti MR, Pedersen M, Sanchez-Laorden B et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3(2), 158-167 (2013).
20. Quintás-Cardama A, Verstovsek S. Molecular Pathways: JAK/STAT pathway: Mutations, inhibitors, and resistance. Clin. Cancer Res. 19(8), 1933-1940 (2013).